Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44020   clinical trials with a EudraCT protocol, of which   7318   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000554-26
    Sponsor's Protocol Code Number:206882
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-09-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-000554-26
    A.3Full title of the trial
    A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received and Responded to GSK3228836 in a Previous Treatment Study
    Estudio prospectivo, multicéntrico (B-Sure) para evaluar la durabilidad a largo plazo de la respuesta virológica sostenida en participantes con hepatitis B crónica tratados y no tratados con nucleósidos/nucleótidos, que recibieron GSK3228836 en un estudio de tratamiento previo y respondieron a dicho tratamiento
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Long-term follow-up study to evaluate durability of sustained virologic response in previous GSK3228836 study participants.
    Estudio de seguimiento a largo plazo para evaluar la durabilidad de la respuesta virológica mantenida en participantes del estudio GSK3228836 previo.
    A.3.2Name or abbreviated title of the trial where available
    B-Sure
    A.4.1Sponsor's protocol code number206882
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04954859
    A.5.4Other Identifiers
    Name:INDNumber:122685
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGlaxoSmithKline Research & Development Limited
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline Research & Development Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd
    B.5.2Functional name of contact pointClinical Trials Help Desk
    B.5.3 Address:
    B.5.3.1Street Address980 Great West Road
    B.5.3.2Town/ cityBrentford, Middlesex
    B.5.3.3Post codeTW8 9GS
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+44208990 9733
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGSK3228836
    D.3.2Product code GSK3228836B (Free acid); GSK3228836A (Sodium salt)
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBepirovirsen
    D.3.9.1CAS number 1403787-62-1
    D.3.9.2Current sponsor codeGSK3228836
    D.3.9.3Other descriptive nameGSK3228836A (Sodium salt)
    D.3.9.4EV Substance CodeSUB208554
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Hepatitis B
    Hepatitis B crónica
    E.1.1.1Medical condition in easily understood language
    Hepatitis B
    Hepatitis B
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10008910
    E.1.2Term Chronic hepatitis B
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To describe long-term durability of sustained virologic response (SVR) as measured by time to loss of SVR in the following two groups:
    • Treatment naïve participants who achieved a complete response. Participants who achieved a complete response in the parent study and either didn't meet the eligibility criteria or met the eligibility criteria and decided not to enrol will be included in the analysis.
    • NA controlled participants who achieved a complete response and discontinued NA treatment per protocol (Section 6.8.1 of the protocol)
    Describir la durabilidad a largo plazo de la respuesta virológica mantenida (RVM) medida por el tiempo hasta la pérdida de la RVM en los siguientes dos grupos:
    •Participantes sin tratamiento previo que lograron una respuesta completa. Se incluirán en el análisis los participantes que obtuvieron una respuesta completa en el estudio original y o no cumplieron los criterios de elegibilidad o sí los cumplieron y decidieron no inscribirse.
    •Participantes controlados con AN que lograron una respuesta completa e interrumpieron el tratamiento con AN siguiendo el protocolo (Sección 6.8.1 del protocolo)
    E.2.2Secondary objectives of the trial
    • Describe changes in disease after NA cessation as measured by time to HBsAg reversion, time to virologic relapse, time to clinical relapse and time to NA retreatment in NA controlled participants who achieved a complete response and discontinued NA treatment.
    • Describe long-term durability of SVR as measured by time to loss of SVR in NA controlled participants who achieved a complete response and are continuing NA treatment.
    • Describe achieving delayed SVR in treatment naive participants who achieved a partial response, and describe time to loss of SVR in participants achieving delayed SVR.
    • Describe achieving delayed SVR in NA controlled participants who achieved a partial response, and describe time to loss of SVR in participants achieving delayed SVR.
    Please refer to the study protocol for the complete list of secondary objectives.
    •Describir los cambios en la enfermedad después del cese de los AN medidos por el tiempo hasta la reversión de HBsAg, el tiempo hasta la recidiva virológica, el tiempo hasta la recidiva clínica y el tiempo hasta la repetición del tto. con AN en los participantes controlados con AN que lograron una resp. completa e interrumpieron el tto. con AN
    •Describir la durabilidad a largo plazo de la RVM medida por el tiempo hasta la pérdida de la RVM en participantes controlados con AN que lograron una resp. completa y continúan con el tto. con AN.
    •Describir el logro de una RVM tardía en los participantes sin tto. previo que lograron una resp. parcial y describir el tiempo hasta la pérdida de la RVM en los participantes que lograron una RVM tardía.
    •Describir el logro de una RVM tardía en los participantes controlados con AN que lograron una resp. parcial y describir el tiempo hasta la pérdida de la RVM en los participantes que lograron una RVM tardía. Lista completa de obj. sec. en protocolo
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participants who have previously received at least one dose of GSK3228836 AND
    a. Achieved SVR (defined as HBsAg <LLOQ and HBV DNA <LLOQ for 24 weeks after the end of previous investigational treatment [GSK3228836
    and/or with or without pegylated interferon] in the absence of rescue medication) and who maintained SVR until the EoS visit in their previous
    treatment study (defined as complete responders to GSK3228836 from the parent study)
    OR
    b. Participants who have previously received at least one dose of GSK3228836 and demonstrated HBsAg reduction of ≥1.0 log10 IU/mL from their treatment study Baseline and also with HBsAg levels <100 IU/mL and HBV DNA <LLOQ for 24 weeks after the end of previous investigational treatment [GSK3228836] until the EoS visit in their previous treatment study in the absence of rescue medication (defined as partial responders to GSK3228836 from the parent study).
    2. Participants who enter the study on stable NA are willing and able to cease their NA treatment in accordance with the NA cessation schedule.
    3. Capable of giving signed informed consent as described in Section 10.1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    1. Participantes que hayan recibido previamente al menos una dosis de GSK3228836 y
    a.Lograran una RVM (definida como HBsAg<LIC y ADN del VHB<LIC durante 24 semanas después del final del anterior tto. en investigación[GSK3228836 y/o con o sin interferón pegilado] en ausencia de medicación de rescate) y mantuvieran una RVM hasta la visita de FdE en su tto. de estudio anterior (definidos como respondedores completos a GSK3228836 del estudio original)
    o
    b.Participantes que hayan recibido previamente al menos una dosis de GSK3228836 y mostraran una reducción del HBsAg de ≥1.0 log10 IU/mL respecto del inicio de su tto. de estudio y también con niveles de HBsAg <100 IU/mL y ADN del VHB<LIC durante 24 semanas después del fin del tratamiento en investigación previo [GSK3228836] hasta la visita de FdE en su estudio previo en ausencia de medicación de rescate (definidos como respondedores parciales a GSK3228836 del estudio original).
    2.Participantes que entren en el estudio estables con AN y deseen y puedan interrumpir su tratamiento con AN de acuerdo al calendario de interrupción de AN.
    3.Capaces de firmar el consentimiento informado como se describe en la Sección 10.1, incluyendo el cumplimiento con los requisitos y restricciones enumeradas en el informe de consentimiento informado (ICF) y en el protocolo.
    E.4Principal exclusion criteria
    1. Participants who have/or are currently participating in another non-GSK interventional clinical study exploring HBV treatment since completing their
    treatment with GSK3228836.
    2. Any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participant in this study.
    1.Participantes que tengan/o estén actualmente participando en otro ensayo clínico intervencionista que no sea de GSK para explorar tratamientos del VHB desde que completaron el tratamiento con GSK3228836.
    2.Cualquier condición que, en la opinión del investigador o del Monitor Médico, contraindique su participación en este estudio.
    E.5 End points
    E.5.1Primary end point(s)
    • Time from achieving SVR in the previous GSK3228836 treatment study to the loss of SVR (first occurrence of either HBsAg or HBV DNA reversion, or first use of any rescue medication).
    • Time from NA cessation to the loss of SVR (first occurrence of either HBsAg or HBV DNA reversion or first use of any rescue medication).
    •Tiempo desde la consecución de la RVM en el estudio de tratamiento anterior con GSK3228836 hasta la pérdida de la RVM (primera aparición de reversión del ADN del VHB o HBsAg, o primer uso de cualquier medicamento de rescate).
    •Tiempo desde el cese de los AN hasta la pérdida de la RVM (primera aparición de reversión del ADN del VHB o HBsAg, o primer uso de cualquier medicamento de rescate).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Defined in the primary endpoints
    Definido en los criterios de valoración primarios
    E.5.2Secondary end point(s)
    • Time from NA cessation to the first occurrence of HBsAg reversion or first use of any rescue medication
    • Time from NA cessation to the first occurrence of virologic relapse or first use of any rescue medication
    • Time from NA cessation to the first occurrence of clinical relapse or first use of any rescue medication
    • Time from NA cessation to NA retreatment
    • Time from achieving SVR in the previous GSK3228836 treatment study to the loss of SVR (first occurrence of either HBsAg or HBV DNA reversion, or first use of any rescue medication).
    • Time from end of treatment in the previous GSK3228836 treatment study to delayed SVR in the absence of rescue medication
    • In the subset of participants who go on to achieve a delayed SVR: Time to the loss of SVR from time of achieving delayed SVR
    • In NA controlled participants who are continuing NA treatment:
    - Time from end of treatment in the previous GSK3228836 treatment study to delayed SVR in the absence of rescue medication
    - In the subset of participants who go on to achieve a delayed SVR: Time to the loss of SVR from time of achieving delayed SVR
    • In NA controlled participants who have discontinued NA treatment:
    - Time from NA cessation to delayed SVR, in the absence of NA retreatment
    - In the subset of participants who go on to achieve a delayed SVR after NA cessation: Time to the loss of SVR from time of achieving SVR.
    • Time from NA cessation to HBsAg loss in the absence of any rescue medication
    • Time from NA cessation to the first occurrence of virologic relapse or first use of any rescue medication
    • Time from NA cessation to the first occurrence of clinical relapse or first use of any rescue medication
    • Time from NA cessation to the first occurrence of NA retreatment
    • Occurrence of anti-HBs (antibody to HBsAg)
    • Occurrence of anti-HBe (antibody to HBeAg)
    • Actual values and changes from Baseline (EoS visit in the parent study) at each study visit in HBsAg, HBV DNA, HBeAg, HBcrAg, HBV RNA levels.
    • Actual values and changes from Baseline (EoS visit in the parent study) at each study visit in HBeAg and anti-HBe.
    • Occurrence of mutations prior to treatment, and post treatment
    •Tiempo desde el cese de los AN hasta la primera aparición de reversión de HBsAg o primer uso de cualquier medicamento de rescate.
    •Tiempo desde el cese de los AN hasta la primera aparición de recidiva virológica o primer uso de cualquier medicamento de rescate.
    •Tiempo desde el cese de los AN hasta la primera aparición de recidiva clínica o primer uso de cualquier medicamento de rescate.
    •Tiempo desde el cese de AN hasta la repetición del tratamiento con AN.
    •Tiempo desde la consecución de la RVM en el estudio de tratamiento anterior con GSK3228836 hasta la pérdida de la RVM (primera aparición de reversión del ADN del VHB o HBsAg, o primer uso de cualquier medicamento de rescate).
    •Tiempo desde el final del tratamiento en el estudio previo de GSK3228836 hasta la RVM tardía en ausencia de medicamento de rescate
    •En el subconjunto de participantes que logran una RVM tardía: Tiempo hasta la pérdida de RVM desde el momento en que se consigue la RVM tardía.
    •En participantes controlados con AN que continúan con el tratamiento con AN:
    -Tiempo desde el final del tratamiento en el estudio previo de GSK3228836 hasta la RVM tardía en ausencia de medicamento de rescate
    -En el subconjunto de participantes que logran una RVM tardía: Tiempo hasta la pérdida de RVM desde el momento en que se consigue la RVM tardía.
    •En participantes controlados con AN que han interrumpido el tratamiento con AN:
    -Tiempo desde el cese de los AN hasta RVM tardía, en ausencia de repetición del tratamiento con AN
    -En el subconjunto de participantes que logran una RVM tardía tras el cese de AN: Tiempo hasta la pérdida de RVM desde el momento en que se consigue la RVM.
    •Tiempo desde el cese de AN hasta la pérdida de HBsAg en ausencia de cualquier medicamento de rescate.
    •Tiempo desde el cese de los AN hasta la primera aparición de recidiva virológica o primer uso de cualquier medicamento de rescate.
    •Tiempo desde el cese de los AN hasta la primera aparición de recidiva clínica o primer uso de cualquier medicamento de rescate.
    •Tiempo desde el cese de los AN hasta la primera aparición de repetición del tratamiento con AN.
    •Aparición de anticuerpos anti-HBs (anticuerpo frente a HBsAg).
    •Aparición de anticuerpos anti-HBe (anticuerpo frente a HBeAg).
    •Valores reales y cambios con respecto al inicio (visita de FdE en el estudio original) en cada visita del estudio en los niveles de HBsAg, ADN del VHB, HBeAg, HBcrAg y ARN del VHB.
    •Valores reales y cambios con respecto al inicio (visita de FdE en el estudio original) en cada visita del estudio en los niveles de HBeAg y anticuerpos anti-HBe.
    •Aparición de mutaciones antes del tratamiento y después del tratamiento.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Defined in the secondary endpoints
    Definido en los criterios de valoración secundarios
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    This is a rollover study from prior GSK3228836 studies designed to assess durability of efficacy of GSK3228836: no further treatment with GSK3228836 will be administered in this study
    Este es un estudio de continuación de estudios anteriores con GSK3228836 diseñado para evaluar la durabilidad de la eficacia de GSK3228836: no se administrará más tratamiento con GSK3228836 en este estudio
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Seguimiento a largo plazo para evaluar durabilidad de efic. respect de estudios prev. de GSK3228836
    This is a long term follow-up study to assess durability of efficacy from prior GSK3228836 studies
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA74
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    China
    Hong Kong
    Japan
    Korea, Republic of
    Malaysia
    Philippines
    Russian Federation
    Singapore
    South Africa
    Taiwan
    Thailand
    United States
    Bulgaria
    France
    Germany
    Italy
    Netherlands
    Poland
    Romania
    Spain
    United Kingdom
    Argentina
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    La última visita para el último participante
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 338
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 112
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2021-09-21. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women Yes
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state10
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 76
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-01-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-12-20
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA